15 September 2014 in Cancer
BACKGROUND: Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers.METHODS: An institutional review board–approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious BRCA mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5‐year intervals to accommodate different age‐related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated.RESULTS: Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a BRCA1 mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a BRCA2 mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1‐34.0; P < .001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0‐10.1; P = .002).CONCLUSIONS: The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings. Cancer 2015;121:269–75. © 2014 American Cancer Society.
26 July 2019 in Current Oncology Reports
1 September 1999 in Journal of Dental Research
Dentin extracellular matrix has been shown to contain components capable of inducing chondrogenesis and osteogenesis at ectopic sites when implanted in vivo, and chondrogenesis in cultures of embryonic muscle-derived fibroblasts (EMF) in vitro. The polypeptide responsible, called the chondrogenic-inducing agent (CIA), has been isolated from a 4.0-M guanidinium hydrochloride extract of demineralized bovine dentin matrix. Following Sephacryl S-100 chromatography, CIA activity was identified in fractions by assay for uptake of [35S]-SO4 into proteoglycan by the EMF after 24 hrs in culture. The active fraction induced the EMF to produce type II collagen mRNA and decrease production of type I collagen mRNA after 5 days in culture. The EMF + CIA, cultured for 4 to 7 wks, formed toluidine-blue- and alizarin-redstainable nodules, indicative of chondrogenic induction. In vivo implants in rat muscle with collagen carrier produced ectopic bone after 7 wks. The CIA was brought to near-homogeneity by reverse-phase high-performance liquid chromatography, tested at each step by EMF [ 35S]-SO4-incorporation assays. The CIA components had masses in the ranges of 6000 to 10,000 Da by both mass spectroscopy and gel electrophoresis. The CIA amino acid composition, NH2terminal, and internal amino acid sequences were determined. These data showed unequivocally that the CIA peptides were derived from bovine amelogenin. The peptides contain the amino-terminal portion of the bovine amelogenin. The presence of these chondrogenic/osteogenic amelogenin-polypeptides in dentin matrix leads us to hypothesize that they may be involved in epithelial-mesenchymal signaling during tooth development interactions-the first time a function has been indicated for these molecules.
1 January 1994 in Journal of Vascular Research
Vascular endothelial cells are an established source of thrombospondin 1 (TSP1), a multifunctional extracellular matrix molecule. TSP1 appears to play an important role in modulating endothelial cell functions such as proliferation, migration, and capillary morphogenesis. In addition, TSP1 has recently been reported to potently inhibit angiogenesis both in vitro and in vivo. To better understand the mechanism underlying the antiangiogenic property of TSP1, endogenous TSP1 production was disrupted in bovine aortic endothelial cells (BAEC) by stable transfection with a vector expressing a TSP1 anti-sense RNA. Stable transfectants in which the antisense vector caused a decrease in TSP1 production were assayed for their ability to form capillarylike cords on gelled basement membrane matrix and for their responsiveness to the angiogenic/chemotactic mediator basic fibroblast growth factor. BAEC in which TSP1 production was disrupted exhibited a ten-fold increase over control BAEC in chemotactic activity to basic fibroblast growth factor and a twofold increase over control cells in the number of capillary-like cords that formed on gelled basement membrane matrix. Thus, the down-regulation of endogenous TSP1 appears to facilitate endothelial cell chemotaxis and capillary morphogenesis. These studies suggest that the modulation of TSP1 production is an important component of the angiogenic response, and support the idea that soluble TSP1 inhibits angiogenesis by interfering with endothelial cell chemotaxis and capillary formation.
1 July 2018 in Gynecologic Oncology
15 June 2016 in The Oncologist
Background.: Mutations in the BRCA1 and BRCA2 genes are associated with increased risk of breast, ovarian, and several other cancers. The purpose of the present study was to evaluate the incidence of cancer in first- and second-degree relatives of BRCA mutation carriers compared with the general population. Materials and Methods.: A total of 1,086 pedigrees of BRCA mutation carriers was obtained from a prospectively maintained, internal review board-approved study of persons referred for clinical genetic counseling at the University of Texas MD Anderson Cancer Center. We identified 9,032 first- and second-degree relatives from 784 pedigrees that had demonstrated a clear indication of parental origin of mutation. Standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated risk estimates according to each subject's age, sex, and ethnicity. Results.: BRCA1 families had increased SIRs for breast and ovarian cancer (p < .001) and decreased SIRs for kidney, lung, prostate, and thyroid cancer and non-Hodgkin's lymphoma (p < .001). BRCA2 families had increased SIRs for breast, ovarian, and pancreatic cancer (p < .001) and decreased SIRs for kidney, lung, thyroid, and uterine cancer and non-Hodgkin's lymphoma (p < .0025). Analysis of only first-degree relatives (n = 4,099) identified no decreased SIRs and agreed with the increased SIRs observed in the overall study population. Conclusion.: We have confirmed previous reports of an association between breast, ovarian, and pancreatic cancers with BRCA mutations. Additional research to quantify the relative risks of these cancers for BRCA mutation carriers can help tailor recommendations for risk reduction and enhance genetic counseling.